APTO Projected Dividend Yield
Com No Par/Aptose Biosciences Inc ( NASDAQ : APTO )Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly hematology. Its pipeline includes small molecule cancer therapeutics designed for single-agent efficacy and to enhance other anti-cancer therapies without overlapping toxicities. The lead compound, Tuspetinib, is an oral kinase inhibitor showing activity as a monotherapy and in combination for relapsed or refractory acute myeloid leukemia (AML), and is being developed for newly diagnosed AML. Luxeptinib targets B-cell malignancies like chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas resistant to conventional treatments. 21 YEAR PERFORMANCE RESULTS |
APTO Dividend History Detail APTO Dividend News APTO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |